Tags

Type your tag names separated by a space and hit enter

Combination Therapy With Intensive Granulocyte and Monocyte Adsorptive Apheresis Plus Ustekinumab in Patients With Refractory Crohn's Disease.
Ther Apher Dial. 2018 Jun; 22(3):295-300.TA

Abstract

Ustekinumab is applied to induce clinical remission in patients with Crohn's disease. Granulocyte and monocyte absorptive apheresis depletes activated myeloid lineage leukocytes and has been applied for active Crohn's disease. This study retrospectively examined the efficacy and safety of combining intensive granulocyte and monocyte absorptive apheresis and ustekinumab for remission induction therapy in refractory Crohn's disease. Between June and September 2017, three consecutive cases (two females) with refractory Crohn's disease were treated with intensive granulocyte and monocyte absorptive apheresis plus ustekinumab. Crohn's disease activity index, and simple endoscopic score for Crohn's disease at baseline and 10 weeks were applied as treatment efficacy outcomes. In all three cases, at week 10, clinical remission was achieved, while simple endoscopic score for Crohn's disease reflected no improvement. Thus, combination therapy with intensive granulocyte and monocyte absorptive apheresis plus ustekinumab appeared to represent a safe and effective intervention for inducing clinical remission.

Authors+Show Affiliations

Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

29790276

Citation

Tanida, Satoshi, et al. "Combination Therapy With Intensive Granulocyte and Monocyte Adsorptive Apheresis Plus Ustekinumab in Patients With Refractory Crohn's Disease." Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, vol. 22, no. 3, 2018, pp. 295-300.
Tanida S, Mizoshita T, Ozeki K, et al. Combination Therapy With Intensive Granulocyte and Monocyte Adsorptive Apheresis Plus Ustekinumab in Patients With Refractory Crohn's Disease. Ther Apher Dial. 2018;22(3):295-300.
Tanida, S., Mizoshita, T., Ozeki, K., Katano, T., Tanaka, M., Nishie, H., Shimura, T., Okamoto, Y., Kubota, E., Kataoka, H., & Joh, T. (2018). Combination Therapy With Intensive Granulocyte and Monocyte Adsorptive Apheresis Plus Ustekinumab in Patients With Refractory Crohn's Disease. Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 22(3), 295-300. https://doi.org/10.1111/1744-9987.12697
Tanida S, et al. Combination Therapy With Intensive Granulocyte and Monocyte Adsorptive Apheresis Plus Ustekinumab in Patients With Refractory Crohn's Disease. Ther Apher Dial. 2018;22(3):295-300. PubMed PMID: 29790276.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Combination Therapy With Intensive Granulocyte and Monocyte Adsorptive Apheresis Plus Ustekinumab in Patients With Refractory Crohn's Disease. AU - Tanida,Satoshi, AU - Mizoshita,Tsutomu, AU - Ozeki,Keiji, AU - Katano,Takahito, AU - Tanaka,Mamoru, AU - Nishie,Hirotada, AU - Shimura,Takaya, AU - Okamoto,Yasuyuki, AU - Kubota,Eiji, AU - Kataoka,Hiromi, AU - Joh,Takashi, Y1 - 2018/05/23/ PY - 2017/11/14/received PY - 2017/11/27/accepted PY - 2018/5/24/pubmed PY - 2018/11/6/medline PY - 2018/5/24/entrez KW - Adsorptive KW - Clinical remission KW - Granulocyte and monocyte apheresis KW - Intensive KW - Refractory Crohn's disease KW - Simple endoscopic score KW - Ustekinumab SP - 295 EP - 300 JF - Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy JO - Ther Apher Dial VL - 22 IS - 3 N2 - Ustekinumab is applied to induce clinical remission in patients with Crohn's disease. Granulocyte and monocyte absorptive apheresis depletes activated myeloid lineage leukocytes and has been applied for active Crohn's disease. This study retrospectively examined the efficacy and safety of combining intensive granulocyte and monocyte absorptive apheresis and ustekinumab for remission induction therapy in refractory Crohn's disease. Between June and September 2017, three consecutive cases (two females) with refractory Crohn's disease were treated with intensive granulocyte and monocyte absorptive apheresis plus ustekinumab. Crohn's disease activity index, and simple endoscopic score for Crohn's disease at baseline and 10 weeks were applied as treatment efficacy outcomes. In all three cases, at week 10, clinical remission was achieved, while simple endoscopic score for Crohn's disease reflected no improvement. Thus, combination therapy with intensive granulocyte and monocyte absorptive apheresis plus ustekinumab appeared to represent a safe and effective intervention for inducing clinical remission. SN - 1744-9987 UR - https://www.unboundmedicine.com/medline/citation/29790276/Combination_Therapy_With_Intensive_Granulocyte_and_Monocyte_Adsorptive_Apheresis_Plus_Ustekinumab_in_Patients_With_Refractory_Crohn's_Disease_ L2 - https://doi.org/10.1111/1744-9987.12697 DB - PRIME DP - Unbound Medicine ER -